Small cell, big promises: targeting small cell lung cancer with CAR T cells

doi:10.21037/tlcr-24-10

Editorial

. 2024 Apr 29;13(4):956-960.

doi: 10.21037/tlcr-24-10. Epub 2024 Apr 24.

Small cell, big promises: targeting small cell lung cancer with CAR T cells

Estela Noguera-Ortega^{1

2}, Steven M Albelda^{1

2}

Affiliations

¹ Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Pulmonary and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

PMID: 38736504
PMCID: PMC11082704
DOI: 10.21037/tlcr-24-10

Editorial

Small cell, big promises: targeting small cell lung cancer with CAR T cells

Estela Noguera-Ortega et al. Transl Lung Cancer Res. 2024.

. 2024 Apr 29;13(4):956-960.

doi: 10.21037/tlcr-24-10. Epub 2024 Apr 24.

Authors

Estela Noguera-Ortega^{1

2}, Steven M Albelda^{1

2}

Affiliations

¹ Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Pulmonary and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

PMID: 38736504
PMCID: PMC11082704
DOI: 10.21037/tlcr-24-10

No abstract available

Keywords: Small cell lung cancer (SCLC); chimeric antigen receptor T cells (CAR T cells); delta-like ligand-3 (DLL3).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-10/coif). The authors have no conflicts of interest to declare.

Comment on

Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y, Tacheva-Grigorova SK, Sutton J, Melton Z, Mak YSL, Lay C, Smith BA, Sai T, Van Blarcom T, Sasu BJ, Panowski SH. Zhang Y, et al. Clin Cancer Res. 2023 Mar 1;29(5):971-985. doi: 10.1158/1078-0432.CCR-22-2293. Clin Cancer Res. 2023. PMID: 36692420

References

1. Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med 2023;388:1284-95. 10.1056/NEJMoa2210859 - DOI - PubMed
1. Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med 2023;29:2844-53. 10.1038/s41591-023-02612-0 - DOI - PMC - PubMed
1. Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol 2024;21:47-66. 10.1038/s41571-023-00832-4 - DOI - PubMed
1. Zhang Y, Tacheva-Grigorova SK, Sutton J, et al. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2023;29:971-85. 10.1158/1078-0432.CCR-22-2293 - DOI - PubMed
1. Depil S, Duchateau P, Grupp SA, et al. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020;19:185-99. 10.1038/s41573-019-0051-2 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med 2023;388:1284-95. 10.1056/NEJMoa2210859 - DOI - PubMed

[2] Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med 2023;388:1284-95. 10.1056/NEJMoa2210859 - DOI - PubMed

[3] Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med 2023;29:2844-53. 10.1038/s41591-023-02612-0 - DOI - PMC - PubMed

[4] Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med 2023;29:2844-53. 10.1038/s41591-023-02612-0 - DOI - PMC - PubMed

[5] Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol 2024;21:47-66. 10.1038/s41571-023-00832-4 - DOI - PubMed

[6] Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol 2024;21:47-66. 10.1038/s41571-023-00832-4 - DOI - PubMed

[7] Zhang Y, Tacheva-Grigorova SK, Sutton J, et al. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2023;29:971-85. 10.1158/1078-0432.CCR-22-2293 - DOI - PubMed

[8] Zhang Y, Tacheva-Grigorova SK, Sutton J, et al. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2023;29:971-85. 10.1158/1078-0432.CCR-22-2293 - DOI - PubMed

[9] Depil S, Duchateau P, Grupp SA, et al. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020;19:185-99. 10.1038/s41573-019-0051-2 - DOI - PubMed

[10] Depil S, Duchateau P, Grupp SA, et al. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020;19:185-99. 10.1038/s41573-019-0051-2 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Small cell, big promises: targeting small cell lung cancer with CAR T cells

Affiliations

Small cell, big promises: targeting small cell lung cancer with CAR T cells

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources